Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2000
06/21/2000CN1257477A Metalloproteinase inhibitors
06/21/2000CN1257474A New nitromethyl ketones, process for preparing them and compositions containing them
06/21/2000CN1257429A Use of low-molecular-weight heparins for preventing and treating cerebral edemas
06/21/2000CN1257072A Novel 1,2-amylic cycle disulfide, its preparation process and medicinal compoisitions containing same
06/21/2000CN1053672C Azasteroid compounds for treating prostatic hypertrophy, their preparation and use
06/21/2000CN1053667C Inhibiting photodecomposition of 3-substituted-2-oxindoles
06/21/2000CN1053665C 2,4-diaryl-1,3-dithiolanes, 2,4-diaryl-1,3-dioxolanes, 2,4-diaryl-1,3-oxathiolanes derivant
06/21/2000CN1053662C New tricyclic amide compounds, processes for their preparation and the pharmaceutical compositions containing same
06/21/2000CN1053570C Pharmaceutical composition of piperidinoalkanol-decongestant combination preparation process
06/20/2000US6077873 Steroid compounds having contraceptive and anti-osteoporosis activity
06/20/2000US6077861 Modulators of the large-conductance calcium-activated potassium (bk) channels, therefore, useful in the treatment of ischemic stroke
06/20/2000US6077856 Hemoregulatory compounds
06/20/2000US6077854 Tri-substituted phenyl derivatives and processes for their preparation
06/20/2000US6077850 Useful for treating cyclooxygenase-2 mediated disorders, such as inflammation and inflammation-related disorders
06/20/2000US6077839 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
06/20/2000US6077833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
06/20/2000US6077828 Method for the prevention and treatment of cachexia and anorexia
06/20/2000US6077827 Family of peptides known as xenoxins
06/20/2000US6077528 Percutaneous preparation
06/20/2000CA2215659C Morphinan hydroxamic acid compounds
06/20/2000CA2198536C Method of reducing tissue damage associated with ischemia
06/20/2000CA2198535C Method of increasing testosterone
06/20/2000CA2001618C Gestodene-containing agent for transdermal administration
06/20/2000CA1341029C Peptidase inhibitors
06/18/2000CA2292481A1 Use of fibrin adhesive for tissue regeneration
06/17/2000CA2292246A1 New hydrazide derivatives, the procedure for preparing them and the pharmaceutical formulations that contain them
06/15/2000WO2000034516A1 Detection of rantes gene promotor polymorphisms
06/15/2000WO2000034515A1 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases
06/15/2000WO2000034451A1 Treatment of pompe's disease
06/15/2000WO2000034338A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034331A2 Analogues of glp-1
06/15/2000WO2000034330A1 Cark protein and nucleic acid molecules and uses therefor
06/15/2000WO2000034314A1 Pharmaceutical compositions comprising quinapril magnesium
06/15/2000WO2000034313A1 Procollagen c-proteinase inhibitors
06/15/2000WO2000034308A2 Protein transduction system and methods of use thereof
06/15/2000WO2000034295A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034285A2 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
06/15/2000WO2000034284A1 2,5-diazabicyclo[2.2.1]heptane derivatives, their preparation and therapeutic uses
06/15/2000WO2000034278A1 Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient
06/15/2000WO2000034277A1 Sulfonamide compounds and uses thereof as medicines
06/15/2000WO2000034276A1 Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
06/15/2000WO2000034274A1 Cyclohexylpiperidine derivatives
06/15/2000WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000WO2000034246A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative
06/15/2000WO2000034245A2 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
06/15/2000WO2000034244A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
06/15/2000WO2000034243A1 N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
06/15/2000WO2000034241A1 N-substituted 2-cyanopyrrolidines
06/15/2000WO2000034230A1 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction
06/15/2000WO2000034228A1 Ion channel modulating agents
06/15/2000WO2000033979A1 Apparatus for separating particles of cohesive material according to size and process
06/15/2000WO2000033875A1 Chemotherapeutic composition and method
06/15/2000WO2000033865A1 Methods of inhibiting ectopic calcification
06/15/2000WO2000033864A1 Remedies for tactile failures
06/15/2000WO2000033861A2 Pharmaceutical compositions containing protein-disulfide isomerases
06/15/2000WO2000033858A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000WO2000033857A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000WO2000033856A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000WO2000033850A1 Remedies for hyperammonemia
06/15/2000WO2000033847A1 Micronized eplerenone compositions
06/15/2000WO2000033844A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
06/15/2000WO2000033842A1 Myt1 kinase inhibitors
06/15/2000WO2000033841A1 Myt1 kinase inhibitors
06/15/2000WO2000033839A1 Non-peptide antagonists of glp-1 receptor and methods of use
06/15/2000WO2000033838A1 Vitronectin receptor antagonist
06/15/2000WO2000033834A1 Use of isatin derivatives as ion channel activating agents
06/15/2000WO2000033829A1 Use of poly (hexamethylene) biguanide for producing an agent for promoting the healing of uninfected wounds
06/15/2000WO2000033828A1 Agent for lowering endothelin levels
06/15/2000WO2000033824A2 Bioflavonoids, anthocyanins and phenolic compounds from cherries for inhibiting inflammation
06/15/2000WO2000033667A2 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants
06/15/2000WO2000015649A9 METHODS OF INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND PREVENTING RESTENOSIS WITH A VECTOR EXPRESSING RB2/p130
06/15/2000WO2000010598A3 Recombinant botulinium toxin for the treatment of mucus hypersecretion
06/15/2000WO2000009711A3 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE α1/β1 (hsGCα1/β1)
06/15/2000WO2000009107A3 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
06/15/2000WO2000005369A3 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
06/15/2000WO2000000469A3 Alkyl ketones as potent anti-cancer agents
06/15/2000WO1999066951A3 Use of bi-specific antibodies for pre-targeting diagnosis and therapy
06/15/2000WO1999058098A3 HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
06/15/2000WO1999045016A3 Novel prodrugs for phosphorus-containing compounds
06/15/2000WO1999014328A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/15/2000WO1999002550A8 Ctl epitopes from ebv
06/15/2000DE19958246A1 Isochinuclidinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende therapeutische Mittel gegen Hypercholesterinämie Isochinuclidinderivate, processes for their preparation containing these compounds and therapeutic agents for hypercholesterolemia
06/15/2000CA2778047A1 Analogues of glp-1
06/15/2000CA2354189A1 Methods of inhibiting ectopic calcification
06/15/2000CA2354150A1 Detection of rantes gene promotor polymorphisms
06/15/2000CA2354044A1 Protein transduction system and methods of use thereof
06/15/2000CA2354040A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
06/15/2000CA2354022A1 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
06/15/2000CA2354021A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative
06/15/2000CA2353773A1 Cark protein and nucleic acid molecules and uses therefor
06/15/2000CA2353522A1 Treatment of pompe's disease
06/15/2000CA2353516A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000CA2353476A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000CA2353475A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2352871A1 Sulfonamide compounds and uses thereof as medicines
06/15/2000CA2352740A1 Procollagen c-proteinase inhibitors
06/15/2000CA2352250A1 Apparatus for separating particles of cohesive material according to size and process
06/15/2000CA2351060A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000CA2351059A1 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
1 ... 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 ... 1564